A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Ex vivo Manufactured Neutrophils for Treatment of Neutropenia—A Process Economic Evaluation
2019
Frontiers in Medicine
Neutropenia is a common side-effect of acute myeloid leukemia (AML) chemotherapy characterized by a critical drop in neutrophil blood concentration. Neutropenic patients are prone to infections, experience poorer clinical outcomes, and require expensive medical care. Although transfusions of donor neutrophils are a logical solution to neutropenia, this approach has not gained clinical traction, primarily due to challenges associated with obtaining sufficiently large numbers of neutrophils from
doi:10.3389/fmed.2019.00021
pmid:30881955
pmcid:PMC6405517
fatcat:vfak3ydvefdopfxpk3iyjnecwu